Metoclopramide Versus Hyoscine Butylbromide in Shortening Duration of First Stage of Labour
NCT ID: NCT05222646
Last Updated: 2022-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
150 participants
INTERVENTIONAL
2022-01-03
2022-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metoclopramide and the Length of First Stage of Labor , a Randomized Controlled Trial
NCT04969120
Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women
NCT01937234
The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies
NCT00409890
Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae
NCT02824679
Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women
NCT03055390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVE This study is designed to compare the effectiveness of metoclopramide versus hyoscine butyl bromide in shortening the duration of the first stage of labour in Abakaliki.
Methods: This would be an equivalence randomized, double-blinded, placebo-controlled trial among nulliparous women in labour Abakaliki to determine the effectiveness of intramuscular Metoclopramide versus intramuscular Hyoscine bromide in shortening the duration of the first stage of labour. One arm will receive a single dose of 10mg of Metoclopramide intramuscularly, another will receive 20 mg of Hyoscine bromide, the third am will receive 1 ml of sterile water(placebo) intramuscularly. The data obtained will be analysed using Statistical Package for Social Science (IBM SPSS) software (version 20, Chicago II, USA) and the intention to treat the concept. Continuous variables would be presented as mean and standard deviation (Mean ± 2SD), while categorical variables would be presented as numbers and percentages. Logistic regression will also be applied where applicable. A difference with a P-value of ≤ 0.05 will be taken to be statistically significant.
Results: The results will be presented in tables from where conclusions will be drawn
CONCLUSION KEYWORD Prolonged labour, Metoclopramide, Hyoscine Bromide, the active phase of labour
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metoclopramide group
They will be receiving10mg of Metoclopramide intramuscularly
Metoclopramide
Will receive single dose of 10mg of Metoclopramide intramuscularly
Hyoscine bromide group
They will be receiving 20 mg of Hyoscine bromide
Metoclopramide
Will receive single dose of 10mg of Metoclopramide intramuscularly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metoclopramide
Will receive single dose of 10mg of Metoclopramide intramuscularly
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uwakwe Emmanuel Chijioke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Uwakwe Emmanuel Chijioke
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Uwakwe DR Emmanuel Chijioke, PART 1
Role: PRINCIPAL_INVESTIGATOR
Alex Ekwueme Federal University Teaching Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AEFUTHA
Abakaliki, Ebonyi State, Nigeria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AEFUTHA/16/07/2020.4/11/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.